Spero Therapeutics, Inc (SPRO) Stock Price

2.43 ▼ -0.02 (-0.82%)
Open: 2.40 Vol: 0 Day's range: 2.38 - 2.445 Apr 02, 15:59 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
SPRO Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 2.44▼ 2.43▼ 2.43▼ 2.36▲ 2.40▲
MA10 2.43▼ 2.43▼ 2.43▼ 2.37▲ 2.35▲
MA20 2.43▼ 2.44▼ 2.40▲ 2.43▲ 2.36▲
MA50 2.43▲ 2.37▲ 2.38▲ 2.35▲ 2.18▲
MA100 2.44▼ 2.37▲ 2.42▲ 2.37▲ 1.66▲
MA200 2.38▲ 2.44▼ 2.36▲ 2.33▲ 1.57▲
  5 mins 30 mins Hourly Daily Weekly
MACD 0.000▲ -0.005▼ 0.002▲ -0.007▼ -0.015▼
RSI 48.368▼ 54.078▲ 56.712▲ 53.402▲ 54.253▲
STOCH 66.667     73.223     59.701     41.653     45.978    
WILL %R -75.000     -28.571     -40.000     -55.102     -45.000    
CCI -58.018     65.141     5.440     -0.888     5.133    
Latest Filters Detected On SPRO
▼ GAP $SPRO Open Gap Down %2 Set Alert
CDL $SPRO Harami Candlestick Pattern Detected Set Alert
Spero Therapeutics, Inc News
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
Tuesday, March 31, 2026 04:21 PM
Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero’s ...
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
Wednesday, March 18, 2026 01:17 PM
About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare ...
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Friday, December 19, 2025 04:59 AM
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare ...
SPRO historical stock data
date open high low close volume
02/04/26 2.40 2.445 2.38 2.43 195,642
01/04/26 2.35 2.48 2.34 2.45 402,251
31/03/26 2.29 2.355 2.21 2.34 485,409
30/03/26 2.388 2.43 2.24 2.24 314,027
27/03/26 2.30 2.44 2.28 2.33 498,713
26/03/26 2.39 2.48 2.34 2.37 482,614
25/03/26 2.39 2.46 2.366 2.41 189,257
24/03/26 2.292 2.47 2.2901 2.37 394,992
23/03/26 2.37 2.4091 2.33 2.35 176,547
20/03/26 2.47 2.47 2.35 2.37 235,757
Quote Details
52wk Low:0.505
52wk High:3.22
Vol:0
Avg Vol(3m):4.8M
1Y Chng:+235.17%
1M Chng:+5.65%
Add to Watch List
More Information
Index US Composite
Market Cap. 135.47M